SI-BONE’s 2021 Sales Grow 23 Percent

Sacropelvic disorder treatment firm SI-BONE yesterday reported fourth quarter and full-year results (ended Dec 31) for its fiscal year 2021.
 
In the fourth quarter, the company’s $25.2 million revenue was a 14 percent rise over the year prior. U.S. revenue rose 13 percent to $23.3 million, and international revenue grew to $1.9 million. The growth was mainly driven by domestic case volume growth in the fourth quarter.
 
For the full year 2021, sales increased 23 percent to $90.2 million compared to 2020. U.S. revenue of $82.7 million represented a 21 percent increase over the prior year, and international sales totaled $7.4 million compared to 2020’s $5.3 million. Again, growth was provoked by a rise in domestic case volumes.
 
In 2021 SI-BONE surpassed 65,000 procedures made by over 2,600 surgeons worldwide. This included 690 active U.S. surgeons in the fourth quarter.
 
“I am pleased with the team’s execution in 2021, as we extended our market leadership, grew our commercial infrastructure, expanded exclusive payor coverage, and ended the year with a record active surgeon base,” said SI-BONE CEO Laura Francis told the press. “As we look beyond the near-term impact from the recent resurgence of COVID-19 on elective procedures and hospital infrastructure, we see strong underlying momentum in our business. In 2022 we will continue to leverage our investments to execute on our long-term strategy and expand the market for sacropelvic surgical solutions.”
 
The company expects this year’s revenue to reach $106 million to $108 million.